Croda’s Avanti Research expands ionizable lipid offering for LNP drug development through Certest collaboration
17 March 2025: Avanti Polar Lipids, LLC, a wholly owned subsidiary of Croda International Plc, and Certest Biotec S.L. (Certest) are pleased to announce a strategic collaboration to expand the market’s access to innovative ionizable lipids. This collaboration enhances Croda's portfolio through its Avanti Research catalogue with the inclusion of a wide range of novel lipids to support lipid nanoparticle (LNP) delivery of next-generation therapeutics.
Certest’s extensive LNP formulation expertise and robust ionizable lipid library in combination with Croda’s future-ready platform offers solutions that enable researchers to overcome challenges associated with LNP delivery and support at every stage of the drug delivery journey—from initial concept through clinical supply and commercialisation. This collaboration provides a trusted partner to navigate each phase of development and offers the expertise needed to help customers successfully bring their drug products to market.
Croda’s Avanti Research is dedicated to offering a comprehensive and diverse portfolio of research products to drive the development of next-generation drug delivery systems and meet evolving market needs. In response to a growing demand for novel ionizable lipids, this partnership empowers Avanti Research and Croda Pharma to introduce new, specialised options to the market, further supporting innovative research and development.
“Avanti Research and Croda Pharma are committed to enabling scientific breakthroughs through our lipid technologies. Partnering with Certest allows us to extend the breadth of our offering of innovative materials to address challenges associated with LNP delivery. Together, we can push the boundaries of next-generation delivery systems.” said Amy Pasley, Global Business Director – Nucleic Acid Delivery.
Nelson Fernandes, General Manager at Certest Biotec, added, “At Certest, we are committed to advancing innovative solutions in the field of nucleic acid therapeutics. Our collaboration with Avanti Research and Croda Pharma marks a significant step forward in ensuring the reliable production of high-quality ionizable lipids and LNP formulations at GMP standards. By combining our proprietary lipid technology with their manufacturing expertise, we aim to support the growing needs of the biopharmaceutical industry and accelerate the development of next-generation therapeutics.”
With a shared commitment to quality, innovation, and scientific excellence, Avanti Research, Croda Pharma, and Certest will combine their strengths to deliver innovative lipid solutions for the global market.
For more information, please contact:
Alexandra Inglis, Croda Pharma press office
Email: alexandra.inglis@croda.com
Contact: +1 732 666 8091
About Croda Pharma
Croda’s Pharma business is a leading partner in the development of excipients and the supply of high purity materials for pharmaceutical formulations and is committed to enabling the next generation of drug delivery systems. The business is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid delivery platforms.
To find out more about Croda Pharma visit: www.crodapharma.com
About Avanti Research
Avanti Research, a Croda brand, creates highly purified lipids, ingredients and services for pharmaceutical and fundamental research, and diagnostics. With a catalogue comprising over 2,000 lipids, Avanti Research also offers custom lipid synthesis and formulation development.
Avanti Research is a trademark of Croda International Plc. Avanti Research is a Croda brand associated with Avanti Polar Lipids, LLC
To find out more about Avanti Research visit: www.avantiresearch.com
About Certest Biotech, S.L.
Certest Pharma specializes in advanced lipid nanoparticle technology, focusing on the development of effective and targeted LNPs for next-generation medicines. Certest’s licensable technology includes top performing ionizable lipids, the main asset, and LNP formulations with excellent performance and which can induce extrahepatic delivery. Having an extensive scientific background and several collaborations, Certest Pharma offers cutting-edge solutions with different payloads of RNA therapies.
Certest Pharma is the fourth business unit of Certest Biotec S.L, established in Zaragoza in 2002 as an innovative and technology-based company. With more than 130 countries as destination, Certest has always based its growth on the research and development of new products and the exploration of new market niches with a great emphasis in control of starting materials for diagnostics and pharmaceutical products.
To find out more about Certest Biotech, S.L. visit: https://www.certest.es/#
Click here to see our new ionizable lipids!
